Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915168 · ClinicalTrials.gov registry record · NA
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
A NA study of Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06915168 is a NA study of Breast Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 20 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06915168, a NA study of Breast Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Informational Intervention
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06915168
The ClinicalTrials.gov registry entry for NCT06915168 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (97% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Survey Administration is the first listed.
NCT06915168 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06915168 about?
NCT06915168 is a clinical study titled "CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer". This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used ...
What is the current status of trial NCT06915168?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-11-13. Estimated completion is 2026-01-31.
What conditions does trial NCT06915168 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT06915168?
The interventions under investigation include: Survey Administration (OTHER), Informational Intervention (OTHER).
Who is sponsoring clinical trial NCT06915168?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915168 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
RECRUITING · NA
-
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
RECRUITING · NA
-
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
RECRUITING · NA
-
A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.